A Follow-up Study to Assess Resistance to ABT-072 in HCV-infected Subjects Administered ABT-072 in Prior ABT-072 Studies
- Registration Number
- NCT00872196
- Lead Sponsor
- AbbVie (prior sponsor, Abbott)
- Brief Summary
This is a follow-up study with no treatment and only samples being collected.
- Detailed Description
The purpose of this study is to evaluate the development of specific viral mutations in response to treatment with ABT-072.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 5
Inclusion Criteria
- Main Selection Criteria: A subject that has received either ABT-072 or placebo in a prior study involving ABT-072.
Exclusion Criteria
- The investigator considers the subject unsuitable for the study for any reasons inclusive of, but not limited to, failure to comply with study procedures in a prior ABT-072 clinical study.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description 1 - Follow-up Study ABT-072 This is a follow-up study with no treatment and only samples being collected.
- Primary Outcome Measures
Name Time Method Analysis of the prevalence of resistance of specific mutations over time will be summarized. Approximately 48 weeks. Analysis of the degree of phenotypic resistance (fold change in susceptibility of ABT-072 compared to wild-type virus) will also be summarized. Approximately 48 weeks.
- Secondary Outcome Measures
Name Time Method Summary of serious adverse events related to study procedures only. Approximately 48 weeks.
Trial Locations
- Locations (1)
Site Reference ID/Investigator# 18222
🇺🇸Los Angeles, California, United States